The GIC (Common Interest groups)

The G.I.C (Groupes d'Intérêt Commun - Common Interest Groups) aim to bring together manufacturers and suppliers (pharmaceutical and biotechnology sectors) to share practices and questions. An A3P GIC must advance the issues presented. The members of the GIC will carry out a collaborative work around the same theme and will return it during an A3P event or through publications (La Vague magazine, scientific and technical guide ...).

Interest-Commun-Group-Pharma-A3p-2023

OBJECTIVES & ACHIEVEMENTS OF THE VARIOUS GIC

Objectives & Achievements

Since August 22, 2022, the new version of the Annex 1 text of the EU GMP has been published. The members of the A3P Annex 1 working group (GIC) will continue their analysis work and share their experiences with the network. (Annex1 GMP EU 2022 .pdf)

  • Dec. 2022: Publication of the A3P Annex 1 CCS GUIDE (pdf in the A3P member area)
  • Oct. 2022 & 2021: Annex 1 Conferences & Workshops at the A3P International Congress (pdf presentations in the A3P member area)
  • Jul. 2020: Comments submitted on the draft “Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice – manufacture of sterile medicinal products” issued by the EMA in 2015) to the EMA
  • Jan. 2019: Article La Vague: A3P International Congress 2018: Key messages from the round table on the revision of Annex 1.
  • Mar. 2018: Article La Vague: EU Annex 1 draft: Proposals from the A3P Annex 1 GIC
  • Apr. 2018: Article La Vague: EU Annex 1 draft: Proposals from the A3P Annex 1 GIC
  • Mar. 2018: Comments submitted on the draft “Annex 1: Manufacture of Sterile Medicinal Products” by the EMA
  • Sept. 2015: Article La Vague: Specific proposed amendments to Annex 1.
Members of the WGI
NameCompanyNameCompanyNameCompany
Antoine AKARHUMANIMSandrine FAVREOCTAPHARMASophiane NAILIIPSEN
Marc BESSONAXYS NETWORKFrançois GUILLOUDELPHARMNicolas RESTENCOURTSANOFI
Nicolas BOURGEOISSANOFIJohn HARGREAVESJHCONSULTANTSEmna SLAMASYNEXIN
Lydia BRETEAULABORATOIRES BOIRONIsabelle HOENENLILLYJonnathan TAFFORINA3P ASSOCIATION
Pierre DEVAUXTHERAXELEric HURTUBISEVALIDAPROJulien TRIQUETCSL BEHRING
Jean-François DULIEREISPEGuy KASDEPKAPHARMASTERJoelle VAN DE KERKHOVEZOETIS
Walid EL AZABSTERISVirginie MARTINONBOEHRINGER INGELHEIMDominique WEILLDOWELI
Objectives & Achievements

Due to the COVID-19 pandemic, remote audits and inspections have become more widespread. This new mode of evaluation presents advantages beyond health constraints, indicating that it will become more common and complementary to traditional practices. This evaluation format requires adopting new practices, which has raised numerous questions that the members of the working group (GIC) have attempted to address by creating a reference document for both auditors and auditees in the form of a Technical Guide:

  • May 2023: A3P Technical Guide “Remote Audit: Recommendations”

The group has set a new objective to work on the publication of a manual on “Preparation Practices for Audits and Inspections.” This manual would not only describe generic best practices but also highlight specific areas of focus and provide tips, such as in the field of sterile manufacturing and the new Annex 1. (Publication coming soon)

Members of the WGI
NameCompanyNameCompanyNameCompany
Pierre ANDRELEO PHARMAJean-Sébastien DUFRASNEMITHRAGael LE FILLIATREOCTAPHARMA
Olivier ANTOINESANOFIAlain EUZENAXYS NETWORKMarie-Noel MAUMUSGMPC
Nathalie BRICARDEXPLEO GROUPMargot GIBERTAMARISKarine PIERRELILLY
Hugues DESREUMAUXROCHEAnne HAYSA3PCécile POIROUXNOVONORDISK
Alexandre DRAPIERGSKSandrine KOLBRECIPHARMAlban RHONEBIOELPIDA
Objectives & Achievements

The complexity and diversity of aseptic processes require tailored Barrier Technology solutions for each of them. The development of new therapeutic alternatives, especially in the field of Advanced Therapy Medicinal Products, necessitates the search for solutions for predominantly manual processes that require high dexterity. The work and sharing of best practices by the members of the Working Group are intended for professionals to optimize their production processes, including validation standards, maintenance standards, and operational standards related to the use of barrier technologies, incorporating international recommendations (Annex 1, ISPE 2005, PHSS 2010), and identifying different “Barrier Technology” solutions.

Members of the GIC
NameCompanyNameCompanyNameCompany
Franck ARETHUSEPIERCANLaurent FLUHRSKANGuillaume MOLLANDINLONZA
Marc BESSONAXYS-NETWORKEric GOHIERJCE BIOTECHNOLOGYCyril MOUNIERGETINGE – LA CALHENE
Pascal CHAMPAGNATBOEHRINGER INGELHEIMGregory GUILLAUMENAFlorelle TOURLETOCTAPHARMA
Patrick COPPENSISOTECXELEtienne HEMBERTLILLY FRANCEAntoine TOUSSAINTGSK VACCINES
Alain DESERTEREADidier MEYERDMCOMPLIANCEJulien TRIQUETCSL BEHRING
Edith FILAIREGROUPE ICARE
Objectives & Achievement

In a context of increasing health authority requirements regarding BFS (Blow-Fill-Seal) technology and the growing demand for vaccines, it is crucial to understand all the necessary steps for filling injectable solutions, to grasp critical parameters, and to set the sterility assurance level at an appropriate level in order to control manufacturing costs and timelines.

Therefore, A3P has decided to create a Working Group on this subject, enabling various concerned industry stakeholders to exchange information and reach common consensus. The ultimate goal is to develop a practical guide for future BFS operators who must manage this type of process, as well as to present the results of this collaborative work in various formats such as conferences and articles.

Objectives of the A3P BFS Working Group: Define a practical guide for industry professionals to understand and effectively manage this technology and its associated processes in the long term.

Members of the WGI
NameCompanyNameCompanyNameCompany
Mohamed Ali AKKARIUNIMEDMélissa CHEVALIERASPEN NDBMohamed HABAZATRYON
Christophe BENOITROMMELAGRodolphe CHOVYTHERAXELMichel LE CADREUNITHER
Delphine BOIVINFAREVA EXCELVISIONLauriane FREYCHETFAREVA EXCELVISIONPascal LUDAESCHERRECIPHARM KAYSERSBERG
Alexandra BRIAUXBOIRONPatrick GERVAISGILBERTClaire PASTOREAGUETTANT
François CABOULETASPEN NDB
Objectives & Achievement

One of the objectives of the Working Group will be to propose a decision tree (methodology, rationale) to support all high-value projects by listing key steps, prerequisites, and points of vigilance throughout the development of a Biopharmaceutical product.

Prerequisites and points of vigilance (non-exhaustive list):

  • Process reproducibility
  • Characterization of standards
  • Level of qualification of analytical methods
  • Analytical process validation
  • Stability testing program
  • Identification of raw materials/suppliers
  • Regulatory strategy
  • Quality documentation
Members of the WGI
NameCompanyNameCompanyNameCompany
ANQUETIN MaximeAIR LIQUIDEGILON NicolasCATALENTRIGOULOT AnneDELPHARM
BAZOT QuentinABL EUROPEHUBERT DorothéeAVANTOR VWRRIOU EdwigeAKTEHOM
BELMON Jean-LouisVIRBACJUST OlivierGENOSAFESANDER PeggyILS
BORTOLIN ElenaFAB’ENTECHLEROY CelineNAOBIOSSLAMA EmnaSYNEXIN
CASSART AnneLSBMARZOUKI FarahPK MEDSOBCZYK AndréCHUV
CECILLE MarieMERCK CTDMOMICHEL SophieSMICHEL ConsultingVAN VYNCHT GéryQUALITY ASSISTANCE
DESNOYER MargauxALTEREGO BIOTECHMONTEMONT LionelPOLYPLUSVERHOEYE FrancisEXOTHERA
DUBOIS LucVALIDAPRONERRIERE OlivierLAPORTE EUROZIEGLER ThierryHUMANIM
DURACHER DavidAMOLYTPARIS JérémySON
EL GUEDDARI MoradYPOSKESIRACHON AlainCORE BIOGENESIS
Objectives & Achievements

Following the revision of Annex 15 published in 2015, A3P decided to create a Cleaning Validation Working Group to support industry professionals in understanding the expectations of Health Authorities and the aforementioned annex. The purpose of this working group was to address all major topics related to cleaning validation, including the selection of worst-case products, determination of acceptance criteria (with a significant focus on PDEs newly requested by Annex 15), equipment train, applicable sampling methods, personnel training, types of cleaning and levels of automation, and other parameters to consider in the cleaning validation exercise such as DHT, CHT, and batch sizes.

Since 2022, the working group has evolved to be called “Cleaning & Disinfection” in line with regulatory expectations. It continues its work for professionals in the industry.

Members of the GIC
NameCompanyNameCompanyNameCompany
BONNEAU GuillaumeNOVO NORDISKAgnès FRANCOVIRBACLaurent SIMONCOPHACLEAN
Sophie BOURGOISASPEN NDBGuillaume GARREAUHALEONDenis STREITTECOLAB
Emmanuel BLANCNOVO NORDISKSolenn JANVIERPIERRE FABREPhilippe TAILLIEZACM PHARMA
Pierre DEVAUXTHERAXELElsa LAJUSFAREVA PAUMarie-Bénédicte TESSIERVETOQUINOL
Soline DIONCEHTRANassim OUALICENEXI FONTENAYAudrey THIERYDELPHARM
Marion DUMONTCHRISTEYNSNicolas PALLUETCONTEC EUROPEDavid UGOLINIDELPHARM
Stéphane DURANDCONFORMATJulie RACAUDLABORATOIRE AGUETTANTAudrey THIERYUPS CONSULTANTS
Audrey FOURCADE LABEILLELFBThomas ROHAUTAKTEHOMLaurianne ZUCHUATVIFOR
Objectives & Achievements

The members of the A3P CPV Working Group aim to further develop the first version of their practical guide with recommendations for industry professionals on the conditions for starting CPV activities, its implementation, and its use (interpretation of results).

Members of the GIC
NameCompanyNameCompany
Damien BONNETPATHEON THERMOFISHERAudrey IMBERT-CLIGNACVETOQUINOL
Véronique BRIANTO-GABIERMAAT PHARMAMohamed KADEMSKYEPHARMA
Stéphane COULEEFAREVA PAUAlain NONNALPHA PHARMA CONSULTING
Sabrina GALLAYASPEN NDBSophie METTEILIPSEN
Valerie HERONSANOFIMurielle PERNELLILLY FRANCE
Michel HERTSCHUHAKTEHOM
Objectives & Achievements

Faced with evolving technologies and modes of IT delivery (Cloud, mobile computing, etc.), the eCompliance Working Group’s efforts aim to optimize current methodologies to maintain flexibility and appropriate risk management. They participate in regulatory text comments (e.g., Annex 11) and share best practices (CSV, etc.).

Members of the GIC
NameCompanyNameCompany
Aymeric BEAUSSANTUCB FARCHIMJean-Louis JOUVECOETIC
Estelle BOROWIECLILLYCedric MAUNOURRIORAVIS
Hugo BOUQUETBIOMERIEUXPascale MOSNIERLABORATOIRES SERVIER
Laurent CLAUSSCEVALionel PELLETIERAKTEHOM
Hervé CLUZEAUDASSYSTEM EXPLEO GROUPThierry PETRUCCICVO EUROPE
Jean-Sebastien DUFRASNEMITHRAElodie RAGNEGETINGE
Aurélien DUJARDINASPEN NDBPierre-François SAMBRONICYRNOS CONSEIL
Loic GUYONNEMERA
Objectives & Achievements

The work of this Working Group has been completed.

Members of the GIC

Authors

  • Alexandre Drapier, Global Quality Compliance Support – GSK Vaccines
  • Sophie Michel, General Manager – Validapro
  • Lionel Montémont, Business Manager – Hedinger
  • Anne Rigoulot, Global Quality Validation Leader – Sanofi

Contributors

  • Caroline Benguerel, IPSEN
  • Stéphane Chabanon, MSD
  • Marie Lamothe, Pierre Fabre
  • Ineke Nackaerts, UCB Pharma
  • Anthony Olivier, Laboratoires Aguettan
  • Karine Vergnaud, Delpharm
  • Ornella Binazon and Etienne Michel, GSK Vaccines

Acknowledgments

  • AFMPS, for hosting us in their premises and dedicating 2 hours to answer our questions. Special thanks to: Jean-Luc Golnez, GMP inspector participating in a working group on Chapters 3 & 5; Aurélie Pol, GMP inspector; Sébastien Herman, GMP inspector trainee; Ahian Zouhir, GMP inspector trainee.
  • ANSM, MHRA and SWISSMEDIC for kindly answering our questions during the conferences.
  • IPEC Europe, and particularly Dr. Frank Milek, President of IPEC Europe.
Objectives & Achievements
Members of the GIC
NameCompanyNameCompany
Olivier ANTOINESANOFIRomain LE DEUNMODERNA
Nadia BEAUDOUXLILLY FRANCEAurélie MIEZE-RICHARDGUERBET
Frédérique CHAZOTPATHEON FRANCEJohanne PIRIOUAKTEHOM
Sylvie COTTAVOZINSTITUT DE RECHERCHE PIERRE FABREAnne RIGOULOTDELPHARM
Aminata DIAGNEINSTITUT PASTEUR DE DAKARSabine SARBACH DETOLLELABORATOIRES SERVIER
Stéphanie JABYLFB
Objectives & Achievement

The management of the lifecycle of analytical methods emerged in the Pharmacopeia Forum in 2013 (PF39(5)) and has received several stimuli related to the concepts of ATP (Analytical Target Profile), method performance (measurement uncertainty, Chapter <1210> of the USP), and control strategy.

The objective is to replace the traditional trilogy of method development/validation/transfer with a continuous approach that allows for iterative steps based on the knowledge and control of the analytical technique implemented to monitor critical attributes of products.

The objectives of the A3P Analytical Method Lifecycle Working Group are:

  • Contribute to the drafting of comments, for example, on the revision of the USP Chapter <1220> “Analytical Procedure Life Cycle.”
  • Define a practical guide for industry professionals that will help them understand the expectations of this phenomenon and manage it in the long term.
  • Continue the work based on future ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) texts (ICHQ14 and ICHQ2(R2)).
Members of the WGI
NameCompanyNameCompanyNameCompany
Pascale AUTHOUARTORIL INDUSTRIEPhilippe CIRERAINNATE PHARMAIsabelle MOINEAUAKTEHOM
Alexandra BELVEZEEUROFINS AMATSI ANALYTICSGérald DE FONTENAYCEBIPHARSoraya SLIMANISTALLERGENES GREER
Jean-François BOECATALENTJean-François DIERICKGSK VACCINESDominique SOTTYTECHNOLOGIE SERVIER
Bruno BOULANGERPHARMALEX BELGIUMMarc FRANCOIS-HEUDESANOFI
Eric CHAPUZETQUALILABCyril MEUNIERNUVISAN
Objectives

The objective of the A3P Lyophilization Working Group is to enable professionals to share best practices and address the concerns of the industry related to the lyophilization process: Annex 1, APS, contamination control, thermal mapping, silicone leaks, optimizing energy consumption, robotics and automation, risk analysis, CIP, SIP, thermal mapping, campaign mode, etc.

Members of the GIC
NameCompanyNameCompanyNameCompany
Sylvain BATIONBIOMERIEUXSandrine FAVREOCTAPHARMAPhilippe SELSISIMA
Vincent DAVIDLIVES INTERNATIONALStéphane GORGERATFERRINGDominique SIERAKOWSKIDS ASEPTIC COMPLIANCE
Elodie DECONINCKGSKBenoit MOREAUGSKDenis TIXIERAMPHENOL SENSORS
Laurent EUZETFAREVA PAUCharles NODOTELLAB
Objectives & Achievements

This group first allows for an assessment of the methods proposed, considered, evaluated, adopted, and rejected by all pharmaceutical industry laboratories, along with their proven advantages and disadvantages. This group is currently working on the creation of a validation guide.

Members of the GIC
NameCompanyNameCompanyNameCompany
Alexis BILLARDSTALLERGENESGuillaume GUIBERTGUERBETFélix MONTERO JULIANBIOMERIEUX
Hélène BLONDELSANOFIKurt JAECQUESGSK VACCINESThierry MULLERMERCK
Thierry BONNEVAYSANOFILaurent LEBLANCBIOMERIEUXEric PETATTERANGA
Arnaud CARLOTTIEUROFINS IDMYKValérie LE JUEZIPSEN PHARMA BIOTECHIlaria SCARFONETHERMO FISHER SCIENTIFIC
Séverine GAUBERTSARTORIUSMarine MARIUSSANOFIPhilippe TAILLIEZACM PHARMA
Objectives & Achievements

This group aims to create a practical and technical guide to demystify the concepts presented in regulations, such as establishing the QTPP (Quality Target Product Profile), defining critical process parameters and critical quality attributes of the product, and the design space, in order to develop and validate a robust and capable process with an effective and appropriate control strategy. This GIC will complement the “CPV Continued Process Verification” and “statistical methodology for the comparative assessment of quality attributes in development” GICs.

Members of the GIC
NameCompanyNameCompany
Isabelle BONNAVENTURESKYEPHARMAChristelle LOURDSANOFI
Nathalie BRICARDEXPLEOViviane NERON DE SURGYVETOQUINOL
Aude COLINDEBIOPHARM INTERNATIONALLaure PLANCHEFAB ENTECH
Nathalie DALLYABBVIEMorgane SPAGNOLAKTEHOM
Eric DREVETONBOEHRINGER INGELHEIMDamien STEFANELLIMEDINCELL
Sandrine DUCLOSVIRBACChung TRINHPATHEON THERMOFISHER
Elodie KEROMNESSTALLERGENESStephane VARLETPROCTER & GAMBLE
Stephan KOPYLAVIRBACBenjamin VITRATFERRING INTERNATIONAL
Romain LE DEUNMODERNA
Objectives & Achievements

The main objectives of the A3P Rouging / Dérouging working Group (GIC) are:

Members of the GIC
NameCompanyNameCompany
Laurence BRAZHALEONElia MOLINAROCHRISTEYNS
Coraline CLAEYSTECHNOCHIMJonnathan TAFFORINA3P
Lionel DUBRAYGSK VACCINESMarc VERNIERATECO TOBLER AG
Walid EL AZABSTERISDelphine VINCENTDIAGAST
Abdel KHADIREKOPE
Objectives & Achievements

Establishing recommendation guides for industry professionals: deployment, use, and maintenance (Life Cycle Management) of Single-Use solutions. Conducting an overview of key issues related to Single-Use Systems (SUS): validation, environmental impact, integrity testing, extractables/leachables, etc. Facilitating information exchange and sharing between users and suppliers to anticipate developments and collaborate on shared standards. Promoting technical solutions using closed systems and containment systems for toxic products.

Members of the GIC
NameCompanyNameCompanyNameCompany
Sébastien BARRYSANOFIJean-Yves DUVALSANOFIPriscille PINGAULTAKTEHOM
Jean-Louis BELMONVIRBACValérie KANDELLILLY FRANCELaurent RODRIGUEZST GOBAIN
Pierre-Michel BODSONUNIVERCELLS TECHAurélie LABOURIERRECIPHARMMarine ROUSSETTECHNIP FMC
Marie-Agnès BOLLFB BIOMEDICAMENTSCharlotte MASYGSK VACCINESJérôme TORRESASEPTIC PROCESS EQUIPMENT
Mehdi BOUKAMIMERCKKatell MIGNOTSARTORIUS STEDIM FMTPhilippe WAGHEMACKERSANOFI
Brigitte DELAPLACEPHARMASEPJean-Philippe MINNEPARKER HANNIFIN
Aurélie DOWNESASPEN NDBWouter PALMAERTSTHERMO FISHER SCIENTIFIC
Eric DEVRETONBOEHRINGER INGELHEIMCamille PERQUINLAPORTE EURO
Objectives & Achievements

The group provided comments on the Guideline “Guidance on ‘Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development’ (EMA/CHMP/138502/2017).” The group participated in the EMA workshop in May 2018 on the “Guidance on ‘Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development’ (EMA/CHMP/138502/2017).”

Members of the GIC
NameCompanyNameCompanyNameCompany
Meriem ABDENNOURSANOFIMourad MELLALGSK VACCINESAnne RIGOULOTDELPHARM
Sébastien LE GUILLOUASPENMarinette MOREAUVETOQUINOLCatherine TUDALSOLADIS
Caroline LEVEDERSANOFIAlice RAILLARDSANOFI
Objectives & Achievements

The work of this GIC is completed.

Members of the GIC
NameCompanyNameCompany
Peggy AUNEYBECTON DICKINSONJulie RACAUDAGUETTANT
Jacqueline BESSETASSYSTEM CAREJean Luc REGAUDIESANOFI R&D
Dominique DISSLILLYJonnathan TAFFORINA3P
Walid EL AZABSTERISJulien TRIQUETCSL BEHRING
Philippe LE GALLAPTAR STELMIDominique WEILLDOWELI
Objectives & Achievements

Particulate Risk Management in Injectable Products

The Particles GIC is the first one created within A3P. It served as a model, and the statutes were drafted to function as other GICs, with the collaboration of experts and the possibility to create sub-working groups. The GIC delivered various outputs, including recommendations, technical documents, and monographs.

The Particles GIC was established in 2013 and was led by Alain EUZEN until 2017. Throughout its existence, the GIC obtained the real collaboration of over 70 experts, whom we sincerely thank for their contributions. They were willing to share their practices, engage in technical discussions, and review and work on tests related to standardization. It was a substantial and beneficial effort for the entire A3P community and beyond. Participants from different European countries (France, Belgium, Switzerland, Germany) showed great commitment.

Given the magnitude of the task and numerous requests following regulatory inspections, the GIC structured itself into four sub-working groups:

  • Sub-Group 1: Primary packaging and transportation, distinguishing between glass articles, elastomers, and disposables or single-use systems (led by François FONVIELLE – Sanofi Pasteur and Benoît LUX – Lilly France).
  • Sub-Group 2: Manufacturing and distribution (led by Alain EUZEN – Sanofi Pasteur).
  • Sub-Group 3: Visual inspection (Romain VEILLON – GSK Vaccines).
  • Sub-Group 4: Complaints, market recalls, and overall statistical data (Patrick TURLIER – GSK).

Thus, the GIC developed a comprehensive understanding of the particulate issue in injectable products.

Knowledge and progress sharing by the GIC took place during four Particles Forums in Le Vaudreuil (Eure) and Lyon between 2013 and 2016, as well as through numerous publications in La Vague and conference presentations (Biarritz Congress, Pharmaceutical Industry Days in Lille, SFSTP seminar in Paris).

Objectives

In a context of increasing regulatory requirements for defect detection, providing producers with the tools to enhance the value of visual inspection processes in the middle of the injectables production chain.

Members of the GIC
NameCompanyNameCompanyNameCompany
Delphine AMOURETASPENAurélien GENETGSKChiara SINITOWILCO
Cécile CHOPINETSANOFIAlban LANGLOISASPEN NDBJonnathan TAFFORINA3P ASSOCIATION
Sabrina DI VICOLEO PHARMASteven MAZOUINNOVONORDISKJean-Michel TASSERITAVI CONSULTING
Gregory DUVALTEOXANEValérie RAUTUREAULILLYElise TOURLETCATALENT
Brahim ELHOSAYNYCENEXIDjonny RIGOTSYNTEGONJeremy UDELEO PHARMA
Objectives & Achievements

This group works on the topic of pharmaceutical water in order to facilitate exchanges among the various concerned industrial stakeholders and reach common consensus to facilitate the implementation of this guideline.

  • December 2020: Conducted two webinars on the latest regulatory developments, their impacts on the design and maintenance of production and distribution systems, as well as the latest trends in monitoring (PDF materials available in the A3P member area)
  • May 2019: Response to the public consultation on the draft issued by the EMA titled “Guideline on the quality of water for pharmaceutical use”
Members of the GIC
NameCompanyNameCompanyNameCompany
Virgile CADORELSANOFIOlivier LAMBERTSANOFIAurélien PERIQUETOCTAPHARMA
Christian COLLETBECKMAN COULTERGuillaume LEDOUXEUROFINS PHARMA QUALITY CONTROLMarie-Laure REMEZYEAU-DI-C
Pierre CULLMANNBWT FRANCEMickael MALLENSANOFISamah RINGAVEOLIA
Michael DE HOVREGSK VACCINESFrédéric MONNIERVEOLIA WATER STIKonrad SAEGESSERSWAN ANALYTICAL
Guy KASDEPKALABORATOIRES PHARMASTER